OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Burris on the Utility of Sacituzumab Govitecan in Metastatic TNBC

August 21st 2020

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the utility of sacituzumab govitecan-hziy in metastatic triple-negative breast cancer.

Dr. Abraham on Future Research in TGCT

August 21st 2020

John A. Abraham, MD, FACS, discusses future research efforts in tenosynovial giant cell tumor.

Dr. Chari on Investigational Belantamab Mafodotin Combos in Myeloma

August 20th 2020

Ajai Chari, MD, discusses next steps with belantamab mafodotin-blmf and combination studies in multiple myeloma.

Dr. Reardon on a Phase 1/2 Trial Examining INO-5401 and INO-9012 in Glioblastoma

August 20th 2020

David A. Reardon, MD, discusses the design of a phase 1/2 trial with INO-5401 and INO-9012 in glioblastoma.

Dr. Richard on Treatment According to Transplant Eligibility in Multiple Myeloma

August 20th 2020

Shambavi Richard, MD, discusses treatment according to transplant eligibility in multiple myeloma.

Dr. Somaiah on Remaining Challenges in Soft Tissue Sarcoma

August 20th 2020

Neeta Somaiah, MD, discusses remaining challenges in soft tissue sarcoma.

Dr. Johnson on the Limitations of Biomarkers in Melanoma

August 20th 2020

Douglas B. Johnson, MD, MSCI, discusses the limitations of biomarkers in melanoma.

Dr. Harrington on the KEYNOTE-048 Trial in Recurrent/Metastatic Head and Neck Cancer

August 20th 2020

Kevin Harrington, BSc, MBBS, PhD, MRCP, FRCP, FRCR, discusses the randomized phase 3 KEYNOTE-048 trial in recurrent/metastatic head and neck squamous cell carcinoma.

Dr. Ravi on the Evolving Treatment Landscape of Advanced Bladder Cancer

August 20th 2020

Praful K. Ravi, MD, discusses the evolving treatment landscape of advanced bladder cancer.

Dr. Jonasch on the Role of Inhibiting HIF-2α in Von Hippel-Lindau Disease–Associated RCC

August 20th 2020

Eric Jonasch, MD, discusses the role of inhibiting hypoxia-inducible factor-2α in Von Hippel-Lindau disease–associated renal cell carcinoma.

Dr. Sekeres on Staging Low- Versus High-Risk MDS

August 19th 2020

Mikkael A. Sekeres, MD, discusses staging patients with myelodysplastic syndromes.

Dr. Pavlick on Longer Follow-Up Data With Cemiplimab in CSCC

August 19th 2020

Anna C. Pavlick, DO, discusses the longer follow-up of the phase 2 EMPOWER-CSCC-1 study with cemiplimab in cutaneous squamous cell carcinoma.

Dr. Atlas on the Promise of Up-Front Cemiplimab in Locally Advanced CSCC

August 19th 2020

Jennifer L. Atlas, MD, discusses the promise of cemiplimab in the treatment of patients with locally advanced cutaneous squamous cell carcinoma.

Dr. Sam on Mitigating Risk of COVID-19 in Elderly Patients With Cancer

August 19th 2020

Christine Sam, MD, discusses strategies to mitigate the risk of the coronavirus disease 2019 in elderly patients with cancer.

Dr. Saba on Emerging Sequencing Strategies in Head and Neck Cancer

August 19th 2020

Nabil F. Saba, MD, FACP, discusses emerging sequencing strategies in head and neck cancer.

Dr. Cuellar on Concerns With Extrapolating Data for Biosimilars

August 19th 2020

Sandra Cuellar, PharmD, BCOP, discusses challenges with data extrapolation for biosimilars.

Dr. Yardley on Challenges With Resistance Mechanisms in HR+/HER2- Breast Cancer

August 19th 2020

Denise Yardley, MD, discusses challenges with resistance mechanisms in hormone receptor–positive, HER2-negative breast cancer.

Dr. D'Amato on the Utility of NGS in Stage I, II, and III Sarcoma

August 19th 2020

Gina Z. D'Amato, MD, discusses the utility of next-generation sequencing in patients with stage I, II, or III sarcoma.

Dr. Hamilton on the Promise of Tucatinib in HER2+ Breast Cancer Brain Metastases

August 18th 2020

Erika P. Hamilton, MD, discusses updated data from the phase 2 HER2CLIMB trial examining tucatinib in patients with HER2-positive breast cancer and brain metastases.

Dr. Ghosh on Differences Among Available BTK Inhibitors in B-Cell Malignancies

August 18th 2020

Nilanjan Ghosh, MD, PhD, compares different BTK inhibitors in B-cell malignancies.